Home > News > “Cell Therapy Innovation 360°: from basic research to patient (...)

“Cell Therapy Innovation 360°: from basic research to patient delivery”

16/05/2019

Launching of the first academic event dedicated to cellular therapies of high scientific level, franco-international chaired by Pr. Gilles Salles, president of CALYM, LYSA and LYSARC and Pr. Jean-Yves Blay.

The CALYM Carnot institute is partner of these scientific days which will take place on 21 and 22 May 2019 in Lyon (Ecole Normale Supérieure).

Why CTI360°?

The development of genetically engineered T-cells constitutes a powerful new class of therapeutic agents that offers a new hope for cancer patients.

CAR T-cells in acute leukemia and diffuse large B-cell lymphoma were recently approved by the FDA and EMA and more than one hundred clinical trials are ongoing. This is definitely an emerging therapeutic breakthrough.

Three AMM have already been issued in hematology and developments follow in haematological malignancies and solid tumors.

The future commercialization of the 1st CAR T-cells will lead to an upheaval in the care of patients at all levels (technological, clinical, organizational, economic, etc.).

What are the objectives of the CTI360 days?

The aim of the Cell Therapy Innovation 360° (CTI 360°) congress is to become a reference in cell-therapy perspectives and issues in Onco-hematology issues. CTI 360° will bring together all the key French and European players in the field: oncologists, hematologists, organ specialists and transplants specialists, hospital pharmacists, immunologists, institutional actors, biotech and pharmaceutical companies.

During these two days, the meeting will adopt a 360° vision of all hot topics in order to:

• Gain insight into mechanisms of action
• Understand the specificities of cellular therapies
• Put into perspective clinical results and current developments
• Understand emerging toxicities
• Share new algorithms
• Define challenges and new models to market access
• Revise the organization of patient management, especially patient journey: on a local, regional, national and international level
• Share experience from the United States and from European countries where cellular therapies are already available.

“We very much hope you can join us and we look forward to welcoming you in May 2019 for what promises to be a therapeutic revolution, a clinical reality and a new breakthrough for any actors fighting against cancer, but more specifically for patients.”
Pr. Gilles Salles and Pr. Jean-Yves Blay

Please, download the program of this event, during which Pr. Guillaume Cartron and Pr. Roch Houot researchers, members of CALYM will speak!

Please download our press release (.pdf)!

For more information: https://www.cti360congress.com/en/